Scientific Advisory Board
The Scientific Advisory Board is a multi-disciplinary international board with expertise in broad areas of technology. This Board focuses on further developing key technologies and applications in the life sciences. Its members are leading experts in a diverse range of life science areas, which include cell therapy processing, cell line engineering, stem cells, cell analytics and biosensors.
“The unbiased advice of the Scientific Advisory Board supports Sartorius in maintaining a diverse, external view of trends in the industry and in guiding Sartorius' technological initiatives.”
Oscar-Werner Reif, Head of Corporate Research, CTO
Michael J. Betenbaugh
Professor of Chemical and Biomolecular Engineering, John Hopkins University, USA
"One of the critical aspects of cell culture engineering is how good is the product and how much of the product do you make. These are really core chemical engineering questions."
Shana O. Kelley
Professor at Department Biomaterials & Biomedical Engineering, University of Toronto, Canada
"Bringing a new technology to market is a huge challenge – and many have failed trying. So you have to be prepared for skeptics. Believing 100 percent in what you're doing ... is key."
Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology, Leiden University Medical Center, Netherlands
"I love science, and I find it fascinating, I like the excitement of learning new things, meeting new people and ideas and getting feedback all the time."
Assistant Professor at the Department of Biomedical Engineering and Lokey Interdisciplinary Center for Life Sciences & Engineering, Technion Israel Institute of Technology, Israel
“I really got exposed to the world of biology and I was fascinated by this world. I chose to take my knowledge from engineering and apply it to answer the [...] most burning questions nowadays in biology“
Professor of Biochemical Engineering, University College London, UK
“The idea is to move companies forward with confidence to enable biopharmaceuticals to move to manufacturing at lower cost, and as a consequence to enable greater populations of patients to benefit.”